Hims & Hers Health (NYSE:HIMS) is set to report its earnings on Monday, Feb 24 after market close. HIMS stock plunged over 25 ...

Raising its price target on the shares to $21, reports The Fly, BofA nonetheless reiterated an "underperform" ( i.e., sell) ...

Shares of Hims & Hers Health plunged Friday after the Food & Drug Administration said a shortage of the active ingredient in ...

Shares of Hims & Hers Health ( HIMS -24.30%) are falling on Friday. The company's stock lost 23.2% as of 1 p.m. ET and lost ...

Telehealth pioneer Hims & Hers Health (HIMS) stock is soaring, with a 12% gain in recent days and a whopping 176% in the last ...

The U.S. FDA has officially declared that Novo Nordisk’s (NVO) popular diabetes and weight loss therapies, Ozempic and Wegovy ...

The telehealth company has been selling a copycat version of a popular obesity drug during the recent shortage.

Hims’s acquisition of Trybe Labs will put it in competition with health industry juggernauts such as Labcorp and Quest ...

Hims & Hers Health, Inc. (NYSE:HIMS) announced the acquisition of a California-based peptide facility to enhance its domestic ...

Hims & Hers Health, Inc. stock surged 1,000% with strategic growth, but high valuation & short interest suggest taking ...

Hims & Hers Health Inc (NYSE:HIMS) shares are soaring Wednesday after the company announced plans to introduce at-home lab ...

We believe there is minimal cause for concern with HIMS stock, which makes it attractive but highly sensitive to adverse events as its current valuation is extremely ...